Ct-HBx promotes HBV-HCC development by enhancing chromatin accessibility to upregulate PAI-1, which is a novel biomarker for HBV-HCC. (IMAGE)

Chinese Medical Journals Publishing House Co., Ltd.

Ct-HBx promotes HBV-HCC development by enhancing chromatin accessibility to upregulate PAI-1, which is a novel biomarker for HBV-HCC.

Caption

Ct-HBx is more potent than WT-HBx in upregulating histone acetyltransferases (GCN5, KAT6A) and chromatin remodeling factors (BAF155, ATRX), enhancing chromatin accessibility of the -1kb promoter and the 3’UTR of PAI-1 to promote PAI-1 expression. PAI-1 functional SNPs (rs2227631-G, rs11178-T, rs1050955-A) increase its expression and interact with HCC-risk HBV mutations to synergistically elevate HBV-HCC susceptibility. Serum PAI-1 levels gradually rise during HBV-induced hepatocarcinogenesis. Higher expression of PAI-1 predict poor prognosis in HBV-HCC, identifying PAI-1 as a novel prognostic and predictive biomarker for HBV-HCC.

Credit

Chinese Medical Journal

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.